SCH 900822
SCH 900822 is a potent and selective glucagon receptor (hGCGR) antagonist that blocks the binding of glucagon to its receptor, thereby reducing hepatic glycogenolysis and gluconeogenesis, thereby lowering blood glucose production. SCH 900822 can be used in the study of type 2 diabetes.
For research use only. We do not sell to patients.
- CAS No.: 1220894-09-6
- Formula: C34H43Cl2N7O2
- Molecular Weight:652.66
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
24 nM
Compound: 1, SCH 900822
|
Displacement of [125I]-glucagon from recombinant human GCGR expressed in CHO cells after 60 mins by scintillation counting analysis
Displacement of [125I]-glucagon from recombinant human GCGR expressed in CHO cells after 60 mins by scintillation counting analysis
|
[PMID: 24527772] |
| CHO | IC50 |
46 nM
Compound: 1, SCH 900822
|
Antagonist activity at human GCGR expressed in CHO cells assessed as inhibition of glucagon-stimulated cAMP production preincubated for 30 mins followed by glucagon induction measured after 45 mins by LANCE assay
Antagonist activity at human GCGR expressed in CHO cells assessed as inhibition of glucagon-stimulated cAMP production preincubated for 30 mins followed by glucagon induction measured after 45 mins by LANCE assay
|
[PMID: 24527772] |
| CHO | IC50 |
>10000 nM
Compound: 1, SCH 900822
|
Antagonist activity at human GLP-1R expressed in CHO cells assessed as inhibition of GLP-1-stimulated cAMP production preincubated for 30 mins followed by GLP-1 induction measured after 45 mins by LANCE assay
Antagonist activity at human GLP-1R expressed in CHO cells assessed as inhibition of GLP-1-stimulated cAMP production preincubated for 30 mins followed by GLP-1 induction measured after 45 mins by LANCE assay
|
[PMID: 24527772] |
Chemical Information
-
CAS No. 1220894-09-6
-
Molecular Weight 652.66
-
Formula C34H43Cl2N7O2
-
SMILES
O=C(C1=CC=C([C@@H](CCC(C)(C)C)N([C@]2(N=C3C4=CC(Cl)=CC(Cl)=C4)CC[C@@H](C(C)(C)C)CC2)C3=O)C=C1)NCC5=NN=NN5
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
[1]. DeMong D, et al. The Discovery of N-((2 H-Tetrazol-5-yl) methyl)-4-((R)-1-((5 r, 8 R)-8-(tert-butyl)-3-(3, 5-dichlorophenyl)-2-oxo-1, 4-diazaspiro [4.5] dec-3-en-1-yl)-4, 4-dimethylpentyl) benzamide (SCH 900822): A Potent and Selective Glucagon Receptor Antagonist[J]. Journal of medicinal chemistry, 2014, 57(6): 2601-2610. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)